Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

HÅKON VOLLDAL APPOINTED CEO IN Q-FREE ASA

Trondheim, Norway, 21 April 2016; We are very pleased to announce that Håkon Volldal is employed as new Chief Executive Officer in Q-Free ASA. Volldal will start in his position in Q-Free ASA on 1 August 2016.Håkon Volldal, a Norwegian citizen, has held several senior positions in TOMRA, where he has been employed since 2004. Currently Volldal holds the position as Executive Vice President and Head of business area TOMRA Collection Solutions. Previous leadership positions in TOMRA include Business Development, R&D/Operations/Product management, Investor Relations and M&A. Prior to

New intelligent materials make healthcare safer

Bactiguard and BioInteractions have received a European research grant aimed at developing a new generation of vascular access catheters, with new bio-smart materials for medical devices. The technology will be developed in a joint project with BioInteractions, UK and Bactiguard, financed by VINNOVA and Innovate UK.Some of the most serious complications found in vascular access are infections and thrombosis. A combination product is to be developed with a long-acting coating featuring a thromboresistant capacity together with an anti-infective biocompatible noble metal surface. - We want

Nordnet interim report January–March 2016

January-March 2016 · Operating income decreased by 9 percent to SEK 301.5 million (329.8) · Profit after tax for the period fell by 34 percent to SEK 72.0 million (108.5) · Earnings per share before and after dilution were down 33 percent to SEK 0.41 (0.62) Highlights · Large fluctuations in the market and high trading activity · Steady growth of the personal loan business · Launch of the mobile app for the Shareville serviceThe first quarter according to CEO Håkan The 2016 trading year had a tough start and all Nordic exchanges declined in the first quarter. The

Mr Green Ltd. selects Kambi Group plc as its Sportsbook provider

Mr Green Ltd, www.mrgreen.com, the award winning online gaming operator, has chosen Kambi Group plc as its Sportsbook supplier. The deal will complement Mr Green’s casino product with Kambi’s premium Sportsbook. Kambi’s agile integration capability will aim to launch its managed Sportsbook at the latest this autumn. Commenting on the deal, Kristian Nylen, CEO, Kambi Group plc said: “The fact that Mr Green has chosen Kambi’s managed service is further testimony to the quality and integrity of our offering. We look forward to empowering Mr Green to create a personalised sports betting

Mr Green online casino selects Kambi as Sportsbook provider.

The award winning online casino Mr Green Ltd. www.mrgreen.com announced today that they have selected Kambi as Sportsbook provider with the aim to launch at the latest this Fall.Jesper Kärrbrink, CEO Mr Green Ltd, comments:  "Mr Green has a reputation of being the gentleman of online gaming. A position that promises honesty, fair play, accurate information and all services attached to the definition of a gentleman."  “We feel that the Kambi Sportsbook has strong focus on quality in terms of availability and reliability, while not sacrificing the quantity aspect. It delivers top of the

Interim results from DIAGNODE-1 indicate clear and desired re-balancing of the immune system after administration of Diamyd® directly into lymph nodes

Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) today announced that Professor Johnny Ludvigsson will present preliminary immunological interim results from four patients in the pilot study DIAGNODE-1 at the diabetes meeting SSSD in Reykjavik 21-22 April. The interim results indicate that administration of a low dose of the diabetes vaccine Diamyd® in lymph glands clearly re-balances the immune system towards a desired so called Th2 response. As previously reported, the treatment appears to be safe and tolerable and the clinical progression seems positive. It is however too

Broken heart linked to other risk factors than heart attack

[PRESS RELEASE 21 APRIL 2016] Broken-heart syndrome is linked to other diseases, but the risk factors for cardiovascular disease are normally lower in these patients. This according to a large registry study of Swedish patients made by Karolinska Institutet. The results, which are published in The Journal of American College of Cardiology, provide confirmation that the prognosis for a broken heart is comparable to that for myocardial infarction.Interest in broken-heart syndrome, or stress cardiomyopathy, has increased dramatically since the turn of the 2000s, but to date knowledge of the

Combitech's interim report for the first quarter 2016

Technical consultancy company, Combitech, an independent subsidiary of the defence and security company Saab AB, releases its interim report for Jan-March 2016 today. Order intake, earnings and margins have all grown strongly during the period.Highlights of the first quarter of 2016:  ·Combitech reinforces its position within self-driving cars and leads or participates in several large projects in Western Sweden – for example Born to Drive and Autopilot Mining. Combitech has also been appointed Core Partner in Vehicle ICT Arena, an open environment for innovation and skills support

Mr Green Ltd selects Kambi as its Sportsbook provider

Mr Green Ltd has selected Kambi as its Sportsbook provider with the aim to launch at the latest this Fall. Kambi will provide Mr Green with a fully managed Sportsbook service. ”Kambi is the perfect partner to deliver the same high standards for our Sportsbook as our players are used to in our highly appreciated casino environment" says Per Norman, CEO of Mr Green & Co AB.“The fact that Mr Green has chosen Kambi’s managed service is further testimony to the quality and integrity of our offering.” says Kristian Nylén, CEO of Kambi Group Plc. We are looking forward to empowering Mr Green

Episurf Medical’s 2015 annual report is now available

Episurf Medical’s annual report for 2015 is available as of today at the company’s website, www.episurf.com. The annual report will be distributed to shareholders and others who made such request. The annual report can also be ordered from Episurf Medical on the following address: Episurf Medical ABStora Skuggans Väg 11SE-115 42 StockholmSweden Or by email: ir@episurf.com   For more information, please contact: Pål Ryfors, CFO, Episurf Medical Tel: +46 709 62 36 69 Email: pal.ryfors@episurf.com   About Episurf MedicalEpisurf Medical is endeavoring to

Interim Management Statement January-March 2016

Highlights during the first quarter · Net asset value amounted to SEK 262,282 m. (SEK 344 per share) on March 31, 2016, a decrease of SEK 9,519 m. (SEK 13 per share) during the quarter, corresponding to a change of -4 percent. Over the past 20 years, annual average net asset value growth, with dividend added back, has been 9 percent. · Within Listed Core Investments, shares in Atlas Copco were acquired for SEK 125 m. · Net cash flow from EQT amounted to SEK 1.2 bn. The value change of Investor’s investments in EQT was flat in constant currency. · The wholly-owned subsidiaries

Notice of Annual General Meeting 12 May 2016 - Cxense ASA

Cxense ASA (OSE:CXENSE) will hold its annual general meeting on 12 May 2016 at 09.00 CET at the Felix Conference Center, Bryggetorget 3, Oslo, Norway. Please find enclosed the notice. The notice with attendance form will be sent to the shareholders today and will also be made available on www.cxense.com/investors. Shareholders wishing to attend the annual general meeting, in person or by proxy, are requested to complete one of the attendance forms sent to the shareholders or to register online on www.cxense.com/investors. At 09.30 CET or after the annual general meeting has been

CXENSE ASA - ANNUAL REPORT 2015

CXENSE ASA - ANNUAL REPORT 2015 OSLO, NORWAY - APRIL 21, 2015 - CXENSE ASA (OSE:CXENSE) TODAY PUBLISHED ITS ANNUAL REPORT FOR THE YEAR ENDED DECEMBER 31, 2015. Highlights: During 2015, Cxense firmly established its position as a world-leading provider of personalization software: - Acquisitions of the companies Maxifier Inc. and Ramp Media to complement the product portfolio and strengthen the advertising and video offerings - Integration of the acquired companies’ organizations, thus improving R&D capacity and market footholds and realizing OPEX synergies - Signing 140

Distribution agreement signed with R-PHARM US for episil®

Lund — 21 April 2016 — Camurus (NASDAQ STO: CAMX) today announces that they have granted R-PHARM US (Princeton, NJ) the exclusive license and distribution rights for episil® oral liquid in the US. episil® oral liquid, is a unique and effective treatment for the pain of oral mucositis, a treatment-limiting side effect of cancer therapies, as well as other oral lesions. Financial terms under this agreement are not disclosed. About oral mucositisOral mucositis (OM) is a common side effect of cancer therapies (chemo- and radiotherapy) and is characterized by painful inflammation and

President and CEO David Nuutinen comments on the results for the first quarter of 2016

Improved operating profit (EBIT), stronger cash flow and lower net debt.Cloetta’s operating profit (EBIT) for the quarter increased to SEK 108m (90). Operating profit, adjusted for one-off items, also increased to SEK 126m (108). Profit after tax amounted to SEK 44m (33). Both operating margin and adjusted operating margin increased to 8.0 per cent (6.9) and 9.3 per cent (8.2), respectively. The higher profit and margins show that our focus has paid off. Sales rose during the quarter, driven by acquisitions. Organic sales were down slightly, facing a strong comparator, at the same time

Interim report January - March 2016

Kai Wärn, President and CEO:“2016 has started in line with our expectations with pre-season demand slightly higher than last year. The operating income continued to be positively impacted by favorable product mix development as well as a successful execution of efficiency improvements and cost reductions. All in all, the operational improvements have more than offset the currency headwind of around SEK -215m as well as the additional costs related to profitable growth initiatives. The operating income increased with SEK 54m to SEK 1,166m (1,112) for the first quarter and the operating

New honorary doctors at Karolinska Institutet 2016

[PRESS RELEASE 21 APRIL 2016] The Board of Research at Karolinska Institutet, Sweden, has appointed three new honorary doctors – Sir Richard Peto, Bob Langer and Alimuddin Zumla – who will have their doctorates formally conferred at a ceremony in the Stockholm City Hall on 13 May 2016.Every year, Karolinska Institutet (KI) confers honorary doctorates to individuals for their vital scientific achievements or significant contributions to the university or humanity at large.  Sir Richard Peto, Honorary Doctor of Medicine (MDhc) The title of Honorary Doctor of Medicine has been awarded

Hafslund – Will not complete the IPO of the power sales business in 2016

In stock exchange notice of 9 December 2015, Hafslund communicated to commence work on separation and a potential initial public offering of the Group's Power Sales business, Hafslund Markets, with the intention to complete an IPO during 2016. Majority owner, City of Oslo, has informed the Board of Directors of Hafslund that they do not want Hafslund to pursue changes in the ownership of the Power Sales business now. - The city council wants to consider such a change in Hafslund's activities in connection with the City of Oslo's overall ownership strategy, that also includes the

Peptonic Medical AB’s (publ) Annual Report 2015 published.

Stockholm 21st April, 2016. - Peptonic Medical (publ)  - a company developing pharmaceuticals based on oxytocin - today announced that the 2015 Annual Report is available on the company’s website   www.peptonicmedical.se and on the AktieTorget website www.aktietorget.se.For more information, please contact;Johan Inborr, CEOTelephone:  +46 708 853 893 E-mail: johan.inborr@peptonicmedical.se About Peptonic Medical AB Peptonic Medical AB (publ) is an innovative Swedish pharmaceutical company developing oxytocin based products e.g. for the treatment of menopausal symptoms, such as

Notice of annual general meeting in Peptonic medical AB (publ)

The shareholders in PEPTONIC medical AB (publ) reg. no. 556776-3064 (the “Company”) are hereby convened to the annual general meeting on Thursday 19 May 2016, at 15.00 in the premises of Gällöfsta Konferens, Biblioteksgatan 29, 114 35, Stockholm, Sweden. Notice etc. Shareholders who wish to participate at the annual general meeting must: - on Friday 13 May 2016 be registered in the share register kept by Euroclear Sweden AB, and - notify his or her intention to attend the general meeting by mail to, att: Dan Markusson, Gustavslundsvägen 143, 167 51 Bromma, “annual general

Mycronic AB (publ), Interim report first quarter January-March 2016

First quarter – strong demand for mask writers but weaker start for SMT equipmentMycronic reports today an increased order intake, increased sales, and a higher EBIT for the first quarter, a period which is typically characterized by lower activity within Mycronic’s segment of the electronics industry. The strong order intake during the quarter increased the order backlog to a record high of SEK 1,516 million, which provides a good basis for continuing favourable development during the current and next year. First quarter January-March 2016 · Order intake reached SEK 794 (471)

There are no items matching the current filter
There are no more items matching the current filter
Back to top